GEORGE HUTTON to Retrospective Studies
This is a "connection" page, showing publications GEORGE HUTTON has written about Retrospective Studies.
Connection Strength
0.164
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.017
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.017
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.017
-
Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler Relat Disord. 2024 Jul; 87:105672.
Score: 0.016
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
Score: 0.016
-
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
Score: 0.015
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
Score: 0.014
-
Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
Score: 0.014
-
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
Score: 0.013
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.012
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.012